Interleukin-10 (IL-10) ameliorates various T-helper type 1 cellmediated chronic inflammatory diseases. Although the therapeutic benefits of IL-10 include antiatherosclerotic effects, pathophysiological effects of IL-10 on vascular remodeling in hypertension have not yet been elucidated. These studies were designed to determine whether sustained IL-10 expression, mediated by an adeno-associated virus (AAV) vector, prevents vascular remodeling and target-organ damage in the stroke-prone spontaneously hypertensive rat (SHR-SP)-an animal model of malignant hypertension. A single intramuscular injection of an AAV1 vector encoding rat IL-10 introduced long-term IL-10 expression. These IL-10-transduced rats had decreased stroke episodes and proteinuria, resulting in improved survival. Histological examination revealed a reduced level of deleterious vascular remodeling of resistance vessels in the brain and kidney of these rats. Immunohistochemical analysis indicated that IL-10 inhibited the enhanced renal transforming growth factor-b expression and perivascular infiltration of monocytes/macrophages and nuclear factor-kB-positive cells normally observed in the SHR-SP. Four weeks after IL-10 vector injection, systolic blood pressure significantly decreased and this effect persisted for several months. Overall, AAV vector-mediated systemic IL-10 expression prevented vascular remodeling and inflammatory lesions of target organs in the SHR-SP. This approach provides significant insights into the prevention strategy of disease onset with unknown genetic predisposition or intractable polygenic disorders.
Introduction
Interleukin-10 (IL-10), a pleiotropic cytokine produced by type-2 helper T (Th) cells, regulates inflammatory reactions. Specifically, it inhibits macrophage activation, T-cell proliferation and proinflammatory cytokine production, including the release of interferon (IFN)-g, IL-2 and tumor necrosis factor-b from Th type 1 (Th1) cells. 1, 2 The importance of inflammation in the pathogenesis of atherosclerosis has been increasingly acknowledged. 3 Recent studies have shown that IL-10 decreases atherosclerotic lesions in the large vessels through an antiinflammatory mechanism. [4] [5] [6] We also reported that in ApoE-deficient mice, a single intramuscular adenoassociated virus (AAV) vector injection resulted in sustained IL-10 expression for over 6 months and improved atherosclerosis. 7 Several evidences suggest that IL-10 regulates endothelial NOS, endothelin-I and heme oxygenase-1 that substantially associate with blood pressure and vascular remodeling of resistance artery in a genetic model of hypertension. Although the overall contribution of inflammation to vascular damage in patients with hypertension remains to be clarified, several forms of experimental hypertension have been used to demonstrate monocyte/macrophage infiltration into the vessels of target organs, such as the brain and kidney. 8, 9 Circulating monocytes are activated in hypertensive patients, 10 and mechanically stretched human monocytic cells induce expression of inflammation-related genes. 11 The spontaneously hypertensive rat (SHR) and its strokeprone substrain, the stroke-prone spontaneously hypertensive rat (SHR-SP), are well-characterized models of genetic hypertension that mimic human essential hypertension. 12 Recent evidence indicates that an inflammatory reaction may underlie the pathogenesis of arteriolosclerosis in the SHR. 13, 14 As a consequence, the role of inflammation in vascular remodeling associated with hypertension-induced organ damage is being researched avidly. However, the role of IL-10 in regulating vascular remodeling of resistance vessels remains to be clarified. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and non-dividing cell types. However, one drawback with their use is that immunological elimination of infected cells often results in transient gene expression in vivo. 15 AAV vectors can efficiently transduce non-dividing skeletal muscle cells and achieve sustained expression of therapeutic genes with minimum inflammatory and immune responses. 16 The transduced muscle cells produce therapeutic proteins, which are secreted into the systemic circulation.
In this study, we hypothesized that an IL-10-mediated anti-inflammatory approach could also retard the progression of vascular remodeling in resistance artery. Here, we demonstrate that AAV-mediated sustained IL-10 expression prevents structural change in resistance artery and peripheral organ damage in the SHR-SP model.
Results

Expression of rat IL-10 in vitro and in vivo
To confirm the expression of AAV1RIL10 in vitro, total cell lysates of human embryonic kidney 293 (HEK293) cells transduced with recombinant AAV (rAAV), and the corresponding conditioned media, were prepared for western blot analysis of rat IL-10. IL-10 was detected in the conditioned medium of HEK293 cells transduced with AAV1RIL10, but not in the AAV1RIL10 cell lysate or the conditioned medium of HEK293 cells transduced with AAV1LacZ (Figure 1a) . These results indicate that IL-10 is secreted from transduced cells. The biological activity of rat IL-10 was confirmed using lipopolysaccharide-stimulated rat splenocytes in vitro. After stimulation with lipopolysaccharide, splenocytes were incubated with the conditioned medium of HEK293 cells transduced with AAV1RIL10 or AAV1LacZ. Production of IFN-g was suppressed by incubation with AAV1RIL10 but not with AAV1LacZ (data not shown), suggesting that rat IL-10 produced by AAV1RIL10 was biologically active. The serum IL-10 concentration in the SHR-SP transduced with rAAV vectors is shown in Figure 1b . Three weeks after gene delivery, serum IL-10 was elevated in a dose-dependent manner and this remained stable over a 6-month period.
Stroke-free duration and neurological score of SHR-SP
To analyze whether stable expression of IL-10 can modify the frequency of stroke episodes in the SHR-SP, the incidences of stroke-associated symptoms were observed (Figure 2a) . Although all control rats (injected with AAV1LacZ or saline) showed stroke-associated symptoms, no stroke-associated symptoms were observed in the rats transduced with AAV1RIL10 (1 Â 10 11 or 1 Â 10 12 genome copies per body (g.c. per body)), even more than 7 months after gene delivery. As the SHR-SP stroke episodes are usually temporary and associated neurological deficits fluctuate significantly at an early stage, the SHR-SP neurological score was determined 6 months after gene delivery. As shown in Figure 2b , control rats revealed marked deterioration, whereas rats transduced per body, n ¼ 5) or saline (n ¼ 5) in the bilateral anterior tibial muscles at 6 weeks of age. Control group is comprised of the AAV1LacZ-injected animals and salineinjected animals. Seizure, paralysis of hindlimb, as well as decreased activity, were all regarded as symptoms. Rats were behaviorally assessed every day. The percentage of stroke-free animals was analyzed by the Kaplan-Meier method. The AAV1-RIL10-treated group showed significantly prolonged stroke-free duration compared with the control group (Po0.001). (b) Neurological deficit scores of SHR-SP. Six months after gene delivery, neurological deficits were evaluated according to a scoring system described in the Materials and methods section. Po0.005 vs control group. g.c., genome copies; IL, interleukin; SHR-SP, stroke-prone spontaneously hypertensive rat.
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Histological evaluation and immunohistochemical examination of the cerebral parenchyma
Representative morphological changes and immunohistochemical analysis in the cerebral parenchyma are shown in Figure 3 . Multiple ischemic foci (Figure 3a) and hyalinotic changes of the arterioles with perivascular cystic change ( Figure 3c) were observed in the vehicletreated group 7 months after gene delivery. In the AAV1RIL10-treated group, arteriolosclerosis and ischemic foci were negligible across the whole brain at the same time point (Figures 3b and d) . Seven months after gene delivery, marked infiltration of ED1-positive (Figure 3e ) or CD11b-positive cells (Figure 3g ) was observed around the pial arterioles of the cerebral parenchyma in the vehicle-treated group. In the AAV1-RIL10-treated group, infiltration of ED1-positive ( Figure  3f ) or CD11b-positive cells (Figure 3h ) in the pial arterioles was rare. Immunoreactivity of collagen type IV on the vessel walls was also higher in the control brain than in the AAV1RIL10-treated brain (Figures 3i and j) .
Protected renal function in SHR-SP
To assess the progression of renal damage, urine was collected over a 24-hour period from rats housed in metabolic cages at 8, 12, 16 and 24 weeks after gene delivery and proteinuria was evaluated. Although the vehicle-treated group showed a significant increase in proteinuria with age, in the AAV1RIL10-transduced group, proteinuria remained low 
Serum biochemistry
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol, blood urea nitrogen and creatinine significantly decreased in the AAV1RIL10-treated group at 6 months after transduction (Table 1) . Serum albumin, glucose and triglyceride were significantly decreased in the control group. Serum cytokine concentration profile is also summarized in Table 1 . IFN-g and TGF-b concentrations significantly decreased in the AAV1RIL10-treated group at 6 weeks after transduction. Morphological changes were evaluated by hematoxylin and eosin (HE; a and b) and periodic acid Schiff stain (PAS; c and d) at 7 months after gene delivery. Scale bars: 100 mm (a and c) and 50 mm (b and d). Representative immunohistochemical examination of the brain at 7 months after gene delivery (e-j). Immunohistochemical analysis of cells expressing ED1 (e and f) or CD11b (g and h) or collagen type IV (i and j) in the cerebral parenchyma of the transduced animals. Scale bars: 100 mm (e-j). SHR-SP, stroke-prone spontaneously hypertensive rat.
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Blood pressure of SHR-SP and morphological changes in the carotid artery Systolic blood pressure of the SHR-SP is shown in Figure 6 . At 6 weeks of age, systolic blood pressure in the control and AAV1RIL10-treated groups was equivalent. Blood pressure gradually increased with age in the control group and reached a plateau of approximately 210-230 mm Hg at 16 weeks of age. Interestingly, systolic blood pressure in the AAV1RIL10-transduced group plateaued at lower values than controls. This effect on the systolic blood pressure persisted over 30 weeks after transduction (Figure 6a) . A significant correlation was observed between serum IL-10 concentration and systolic blood pressure at 9 weeks after transduction ( Figure  6b ). Histological changes in the carotid artery 6 months after vector administration are summarized in Figure 6c . Compared with the control group, carotid artery integrity was well preserved in the AAV1RIL10-treated group. Quantitative analysis of carotid diameter and media thickness is shown in Figure 6d . Both of these parameters decreased significantly in the AAV1RIL10-treated group.
Prolonged survival of SHR-SP
Survival of SHR-SP transduced with AAV1RIL10 (1 Â 10 11 or 1 Â 10 12 g.c. per body), AAV1LacZ or saline was evaluated by Kaplan-Meier survival analysis ( Figure 7) . Transduction of the SHR-SP with AAV1RIL10 significantly prolonged survival compared with that of controls (AAV1LacZ or saline; n ¼ 10 for each group; Po0.001).
Discussion
Here we demonstrate that sustained IL-10 expression can prevent the progression of arteriolosclerosis and associated target-organ damage in the SHR-SP. A single intramuscular injection of an AAV1-based vector encoding IL-10 achieved long-term systemic IL-10 expression. The resultant IL-10-transduced rats showed an improvement in proteinuria, as well as prolonged stroke-free duration and survival. Histological examination revealed a reduction in brain arteriolosclerosis and nephrosclerosis when compared with control rats. Immunohistochemical examination confirmed decreased infiltration of monocytes/macrophages and NF-kB-positive cells in the brain and renal arteriolosclerotic lesions of these rats. IL-10-transduced rats also exhibited a sustained decrease in the systolic blood pressure compared with controls.
The AAV vector, derived from a non-pathogenic parvovirus, can transduce non-dividing neuronal and skeletal muscle cells, and can also achieve long-term transgene expression in vivo with minimal inflammatory and immune responses. 17, 18 Intramuscular injection of the vector is used to transduce the skeletal muscle in vivo and the resultant transduced muscle cells produce the encoded proteins, which are secreted into the systemic circulation. Preclinical and clinical investigations using AAV2-based vectors have demonstrated efficient neuronal transduction and therapeutic benefits in neurodegenerative diseases with minimum adverse effects. 18 However, the application of this technique might be limited because of insufficient levels of transgene expression in other tissues. 19 The AAV serotype 1-based vector has distinct receptors that may promote the initial viral binding and entry into muscle cells, leading to a more efficient transduction to skeletal muscle than AAV2-based vectors. 20 We therefore utilized an AAV1-pseudotyped vector in this study. We confirmed the presence of sustained and adequate IL-10 serum levels in SHR-SP after a single intramuscular injection of AAV1IL10.
We initially evaluated the effects of IL-10 on SHR-SP behavior. IL-10-tranduced rats showed decreased strokeassociated symptoms compared with the untreated controls. This behavioral improvement might be Accumulating evidence supports the notion that hypertension is the biggest risk factor for brain lacunar syndrome and intracerebral hemorrhage, suggesting that high blood pressure affects the local injury of intracerebral arteries. 21 Degenerative vascular changes, similar to those seen in human essential hypertensives, occur in the brain of the SHR and SHR-SP. 22 We demonstrated that long-term systemic IL-10 expression prevented the arteriolosclerotic lesions, normally characterized by fibrinoid necrosis and monocyte/macrophage infiltration, in cerebral arteries of the SHR-SP. We also observed reduced serum levels of IFN-g, a proinflammatory cytokine released by Th1 cells, in the IL-10-transduced rats. A Th1-dominant T-cell population is associated with progression of hypertensive organ damage. 17 However, IL-10 is reported to deactivate monocytes by reducing IFN-g production, 23 thereby improving atherosclerotic lesions by shifting the Th pattern from Th1-dominant to Th2-dominant. These observations suggest that IL-10 might regulate vascular inflammation by modulating Th imbalance. In addition, IL-10 inhibits the expression of adhesion molecules and matrix metalloproteinases, as well as smooth muscle cell proliferation. [24] [25] [26] [27] [28] These IL-10 effects might regulate local vascular inflammation and remodeling, also leading to an improvement in arteriolosclerosis. Clearly, further investigations are required to clarify the mechanism(s) by which IL-10 improves hypertension-associated vascular damage in more detail.
In this study, we also observed that activated NF-kBpositive cells accumulate in renal arteriolosclerotic lesions of the SHR-SP. The transcription factor, NF-kB, is activated by a wide variety of proinflammatory molecules, such as IL-8, macrophage chemotactic protein-1, intercellular adhesion molecule-1, vascular-cell adhesion molecule-1 and E-selectin. [29] [30] [31] Monocyte infiltration into the small renal arteries stimulates NF-kB activation, leading to chemokine and cytokine expression in the kidney. NF-kB is also known to be activated in the course of vascular inflammation and renal injury in the SHR. 32 In contrast, IL-10 directly inhibits NF-kB activation in macrophages. 33 In this study, IL-10-transduced rats showed a decrease in activated NF-kB-positive cells in the renal arteriolosclerotic lesions of SHR-SP, which might reflect reduced inflammatory activity within these lesions. Abbreviations: AAV, adeno-associated virus; SHR-SP, stroke-prone spontaneously hypertensive rat. The transduction protocol is identical to that used in Figure 2 . Serum biochemical analysis of the SHR-SP was performed at 6 months after injection. Serum cytokine profile in the AAV1RIL10-transduced SHR-SP (IL-10) or saline-treated SHR-SP (control) was also analyzed at 6 weeks after injection. 
IL-10 prevents end-organ damage in SHR-SP T Nomoto et al
We further investigated the role of TGF-b in renal arteriolosclerosis and nephrosclerosis. TGF-b, a multifunctional growth factor, plays an important role in tissue repair and fibrosis by regulating cell proliferation and differentiation. Recent evidence supports the notion that overproduction of TGF-b may cause the vascular remodeling and other long-term sequelae of hypertension, including nephrosclerosis. 34, 35 TGF-b may regulate blood pressure levels by stimulating endothelin-1 mRNA expression and releasing renin from the juxtaglomerular cells of the kidney. 34, 36 It can also increase vascular compliance by promoting deposition of extracellular matrix components in the vessel walls. 37 Moreover, treatment of the Dahl salt-sensitive rat strain with an anti-TGF-b antibody significantly reduces blood pressure, proteinuria and albuminuria. 38 In the SHR-SP, glomerular and tubulointerstitial TGF-b expression, as well as cellular phenotypic modulation, accelerates the progression of renal fibrosis and nephrosclerosis. 39 Enhanced TGF-b expression also promotes the hypoxiainduced tubulointerstitial transdifferentiation of proximal tubular cells. 40 We found evidence for renal arteriolosclerosis and nephrosclerosis, along with enhanced TGF-b expression, in the renal epithelial cells and sera of the SHR-SP. In contrast, the IL-10-transduced rats had preserved renal structures and decreased TGF-b expression compared with the controls. These results indicate that IL-10-mediated TGF-b regulation may be involved in the physiological protective mechanism against renal arteriolosclerosis and the emergence of hypertension. Survival after transduction of the SHR-SP was estimated by Kaplan-Meier analysis. The experimental protocol is identical to that used in Figure 2 . The SHR-SP transduced with AAVRIL10 showed significantly prolonged survival (Po0.001). IL, interleukin; SHR-SP, stroke-prone spontaneously hypertensive rat.
The cholesterol-lowering effect of sustained, systemic IL-10 expression we observed is consistent with our earlier study. 7 The decreased levels of glucose and triglyceride that appeared in the control group may be associated with malnutrition after stroke episodes. Decreased serum albumin levels in this group might result from proteinuria caused by hypertensive renal dysfunction. Importantly, serological studies showed no apparent adverse effects in the IL-10-transduced group.
As a first step toward the future therapeutic investigation, we tried rAAV-mediated IL-10 transduction to prevent vascular remodeling and inflammatory lesions in this study. Here, we have shown protective function of IL-10 against malignant hypertension, although it would be more important to investigate the therapeutic effect on developed hypertension. This protective approach also provides significant insights into the prevention strategy of disease onset in patients with genetic predisposition or intractable polygenic disorders.
In conclusion, we have provided the first evidence that AAV vector-mediated stable IL-10 expression prevents arteriolosclerosis and end-organ damage in the SHR-SP, leading to decreased stroke episodes and prolonged survival. Although the mechanisms underlying the antihypertensive effect of IL-10 require further clarification, its vasculoprotective effect might involve an antiinflammatory process. Our results suggest that IL-10-mediated vascular protection would be an alternative effective therapeutic strategy to prevent the progression of refractory hypertensive disorders.
Materials and methods
Cloning of rat IL-10 and plasmid construction
Rat IL-10 was cloned from cDNA of rat splenocytes by PCR using the following primers: 5 0 -GCACGAGAGC CACAACGCA and 5 0 -GATTTGAGTACGATCCATT TATTCAAAACGAGGAT. The 1.3-kb PCR product was cloned into pCR2.1 by using a TA cloning kit (Invitrogen Corp., Carlsbad, CA, USA). The cloned PCR-amplified fragment was verified by sequencing. The resultant plasmid, pCR2.1RatIL-10, was digested with EcoRI, and then the rat IL-10 gene fragment was inserted into the EcoRI site of p3.3CAG-WPRE, which contains a CAG promoter and woodchuck post-transcriptional regulatory element (WPRE). Finally, the entire expression cassette was inserted between the AAV2-derived inverted terminal repeats (ITRs) in a pUC-based proviral plasmid, pAAVLac Z, to form pWCAGRIL10W.
Recombinant adeno-associated virus production
Recombinant AAV was propagated according to a threeplasmid transfection adenovirus-free protocol. 41 Briefly, 60% confluent HEK293 cells were co-transfected with the proviral plasmid (pWCAGRIL10W or pAAVLac Z), AAV-1, chimeric helper plasmid, p1RepCap, and adenoviral helper plasmid, pAdeno, to produce rAAV expressing either rat IL-10 (AAV1RIL10) or Escherichia coli b-galactosidase gene (AAV1LacZ). Resultant crude virus lysates were purified through two rounds of CsCl twotier centrifugation. 16 The physical titer of the viral stock was determined by dot blot hybridization with plasmid standards.
Western blot analysis and functional analysis of rat IL-10 in vitro HEK293 cells were infected with AAV1RIL10 or AAV1-LacZ at 1 Â 10 4 g.c. per cell. The supernatant and cell lysate were harvested 72 h after infection. Cells were lysed in a lysis buffer (10 mM Tris-HCl, 150 mM NaCl and 1% NP-40 (pH 7.6)) with Complete Mini (Roche Diagnostics, Mannheim, Germany). The supernatant was concentrated 10-fold using centricon YM-10 (Millipore, Bedford, MA, USA). Ten micrograms of cell lysate or 10 ml of concentrated conditioned medium was subjected to electrophoresis on 10% SDS-polyacrylamide gel electrophoresis under reducing conditions and transferred to a nitrocellulose membrane. The membrane was blocked and incubated with a 1:1000 dilution of mouse anti-rat IL-10 polyclonal antibody (Genzyme Techne, Minneapolis, MN, USA). The membrane was then rinsed and incubated with a 1:1000 dilution of peroxidase-linked anti-mouse IgG antibody (Amersham Pharmacia Biotech, Buckinghamshire, UK). Immunoreactive bands were visualized using the ECL Western blotting kit (Amersham). The biological activity of rat IL-10 was determined as follows: HEK293 cells were transduced with AAV1RIL10 at 1 Â 10 4 g.c. per cell. Seventy-two hours after infection, this supernatant was recovered and the concentration of IL-10 in the supernatant was determined using the Rat Biotrak ELISA System (Amersham). Rat primary splenocytes were incubated with the IL-10-containing supernatant. Thirty minutes after incubation, lipopolysaccharides were added at a concentration of 10 ng ml
À1
. Twenty-four hours later, the concentration of IFN-g in the supernatant was determined using the Rat Biotrak ELISA System (Amersham).
Intramuscular injection of rAAV and physiological analysis
Male SHR-SP at 6 weeks of age were purchased from Japan SLC (Shizuoka, Japan) and used in the transduction study. The rats were housed under controlled conditions of constant temperature and humidity and exposed to 12-h light/dark cycle. The rats had free access to chow and tap water. All animal studies were performed in accordance with the guidelines issued by the committee on animal research of Jichi Medical School and approved by its ethics committee.
Male SHR-SP were injected with AAV1RIL10 (1 Â 10 11 or 1 Â 10 12 g.c. per body; n ¼ 5 for each group), AAV1-LacZ (1 Â 10 11 g.c. per body; n ¼ 5) or saline (n ¼ 5) into the bilateral anterior tibial muscles at 6 weeks of age. Control group comprised AAV1LacZ-injected animals and saline-injected animals. From 8 weeks of age, rats were fed a controlled diet (Funahashi SP diet; Funahashi, Chiba, Japan). The systolic blood pressure of rats was measured weekly using a manometer tachometer (Natsume KN-210; Natsume Seisakusho, Tokyo, Japan) with a tail-cuff method. An average of five readings was recorded for each animal after they had acclimatized to the environment. Urine was collected from rats in metabolic cages for a 24-h period at 8, 12, 16 and 24 weeks after gene delivery. Urinary protein levels were determined by the Lowry method. Rats were monitored on a daily basis for behavioral signs of stroke. Stroke-associated symptoms, such as seizure, hindlimb IL-10 prevents end-organ damage in SHR-SP T Nomoto et al paralysis and decreased activity, were also assessed as physiological parameters. When any one of these symptoms occurred in the SHR-SP, animals were regarded as stroke positive. Six months after gene delivery, neurological deficits were evaluated according to the following scoring system: 42 (0) normal; (1) slight decrease in motor activity; (2) marked decrease in motor activity or hyperirritability; (3) no walking (decreased responsiveness); (4) inability to stand without support or paralysis of hindlimbs.
Serum biochemistry
Serum samples were collected from the tail vein and stored at À80 1C. Serum biochemistry values, including the concentration of albumin, AST, ALT, total cholesterol, triglyceride, glucose, blood urea nitrogen and creatinine, were estimated using standard procedures. IFN-g, IL-4 and IL-10 concentrations in sera were measured by using a BIOTRAK ELISA system (Amersham). The concentration of TGF-b was determined by commercial enzymelinked immunosorbent assay (BioSource International, Camarillo, CA, USA).
Histological examination
Seven months after gene delivery, anesthetized rats were perfused with 50 ml of saline, followed by 100 ml of cold 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brain, kidney, descending aorta and carotid artery were fixed in the same fixative and finally embedded in paraffin. Three-micrometer thick sections were stained with hematoxylin and eosin, periodic acid Schiff, oil red O and elastica van Gieson by standard methods for light microscopy.
Immunohistochemistry
Immunohistochemical staining was performed using a standardized streptavidin-bioin-peroxidase method. A mouse monoclonal antibody against rat ED1 (1:100; Serotec, Oxford, UK), a mouse monoclonal antibody against rat CD11b (1:100; Serotec), a rabbit polyclonal antibody against human collagen type IV (1:100; Progen, Heidelberg, Germany), a mouse monoclonal antibody against TGF-b (1:100; Chemicon, Temecula, CA, USA) and a mouse monoclonal antibody against NF-kB p65 subunit (1:50; Chemicon) were used as primary antibodies. Seven months after gene delivery, anesthetized rats were perfused, as described above. Four hours after fixation, the brain and kidney were transferred to 30% sucrose in 0.1 M phosphate buffer (pH 7.4) for cryoprotection and stored at 4 1C overnight. The tissue was frozen in OCT compound (Tissu-Tek; Sakura Finetek, Torrance, CA, USA) at À20 1C and 10-mm thick sections were sliced with a cryostat. The sections were washed and permeabilized with phosphate-buffered saline (PBS) containing 0.5% Triton-X for 10 min, followed by incubation in PBS containing 50 mM glycine. Slides were then washed three times with PBS and blocked with PBS containing 1% bovine serum albumin for 20 min. Internal peroxidase activity was quenched by incubation in PBS buffer containing 0.3% hydrogen peroxide with 0.1% sodium azide. After washing with PBS for three times, the sections were incubated with primary antibodies overnight at 4 1C followed by incubation with biotinylated anti-rabbit or anti-mouse IgG antibody (Vector Laboratories, Burlingame, CA, USA) and horse radish peroxidase-labeled streptavidin (Vector Laboratories). The reaction was visualized by using the Vector SG kit (Vector Laboratories), and nuclear fast red was used for counterstaining.
